UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of October 2023
001-36203
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its charter)
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On October 26, 2023, Can-Fite BioPharma Ltd. issued
a press release entitled “Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs”. A copy of this
press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Date: October 26, 2023 |
By: |
/s/ Motti Farbstein |
|
|
Motti Farbstein |
|
|
Chief Executive Officer and
Chief Financial Officer |
2
Exhibit 99.1
Can-Fite to Harness Artificial Intelligence
to Develop Novel Anti-Cancer Drugs
| ● | Can-Fite signed an agreement with Collaborations Pharmaceuticals,
a leading expert in Artificial Intelligence and Machine Learning |
PETACH TIKVA, Israel, October 26, 2023 -- Can-Fite BioPharma Ltd. (NYSE
American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and
inflammatory diseases, today announced that it entered into an agreement with Collaborations Pharmaceuticals, Inc. (CPI) to develop anti-cancer
drugs utilizing artificial intelligence (AI) and machine learning (ML) techniques. This project will aim to develop a next-generation
A3 adenosine receptor drug agonists that significantly reduce the development time and cost of bringing such drugs to market.
CPI will utilize, apply and use AI and ML tools, including their MegaSyn
generative AI method, to design new molecules with high affinity and selectivity to the A3AR Can-Fite target. CPI will also perform the
chemical synthesis of the newly designed molecules with the ultimate goal of developing novel and robust anti-cancer drug candidates.
Can-Fite will perform the testing of the biological anti-cancer effects and validate the molecular mechanism of the novel, chemically
synthesized drug candidates.
“Our vision is to deliver in silico small molecule drug
candidates in a better and faster way to patients via a collaboration with Collaborations Pharmaceuticals. Our accumulated experience
of bringing anti-cancer drugs which target the A3AR from lab to patients will be implemented into this AI drug development project,”
stated Prof. Pnina Fishman, Executive Chairman and CSO at Can-Fite.
“We are delighted that Can-Fite chose our team of experts for
this AI-led drug discovery collaboration and look forward to demonstrating what our technology can do,” said Sean Ekins, PhD, DSc.,
CEO and Founder of Collaborations Pharmaceuticals, Inc. We also look forward to complementing their outstanding scientific approach with
our integrated technology platform and ability to generate novel and selective molecules.”
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF)
(TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion
dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently
reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite’s cancer and
liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of steatotic liver disease (SLD), a Phase III pivotal
trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted
Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug
Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma.
CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent
safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.can-fite.com.
About Collaborations Pharmaceuticals:
Collaborations Pharmaceuticals, Inc. developed
MegaSyn for generative drug design. In addition they have developed Assay Central® software for data curation and machine
learning as well as curated model collections such as MegaTox®, MegaTrans® and MegaPredict®.
Collaborations Pharmaceuticals, Inc. performs research and development on innovative therapeutics for multiple rare and neglected diseases
and consults for pharmaceutical and consumer product companies. For more information, http://www.collaborationspharma.com/
Forward-Looking Statements
This press release may contain forward-looking
statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those
relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of
forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,”
“should” or “anticipate” or their negatives or other variations of these words or other comparable words or by
the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated
or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause
Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements
to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and
needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties
of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical
trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully
complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of
other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our
ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model
and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual
property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights
of others; competitive companies, technologies and our industry; risks related to the COVID-19 pandemic and the Russian invasion of Ukraine;
risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political
and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time
to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 30, 2023
and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation
to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise,
except as may be required by any applicable securities laws.
Contact
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
Collaborations Pharmaceuticals, Inc.
Sean Ekins, PhD., D.Sc.
CEO and President
sean@collaborationsPharmaceuticals.com
Can Fite BioPharma (AMEX:CANF)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Can Fite BioPharma (AMEX:CANF)
Gráfica de Acción Histórica
De May 2023 a May 2024